It was reported 15 Sep 2009 by CNBC

The Food and Drug Administration approved the new swine flu vaccine Tuesday, a long-anticipated step as the government works to get vaccinations under way next month. Studies in children and pregnant women are continuing. The vaccine approved Tuesday is made by CSL of Australia; Switzerland's Novartis; Sanofi-Pasteur of France; and Maryland-based Medimmune, which makes the only nasal-spray flu vaccine.

FDA approved “the vaccine”? Four different vaccine manufacturers are listed and they all make a completely different product, each as different as chalk and cheese, yet they are all reported as “the new swine flu vaccine”

For example the CSL product, we are led to believe has no adjuvants, see Panvax post for details. A report on trials that started also on 15 Sep 2009 in Colorado using Novartis vaccine, detail they do use the adjuvant SQUALENE, it's named in the consent forms for participants, see – Vactruth

It is interesting that the FDA approved the CSL product (Panvax) while the equivalent Australian (TGA) was not so quick to do so, the Australian Government took unusual action to exempt Panvax from regulations requiring approval and registration before it is dispensed.

Many more big pharma companies are all busily concocting their own H1N1 so called vaccinations. Baxter International Inc. filled a patent for a swine flu vaccine in August 2008. To make a vaccine, researchers must first make a recombinant virus. Baxter, some time prior to Aug 2008, produced a H1N1 strain in the kidney cells of African Green Monkeys.

Even after the most stringent filtering and purification procedures, a small portion of this monkey DNA and cell protein remains in the end product vaccine. According to Dr. M Hilleman, the AIDS virus was unleashed upon humans when the Merck pharmaceutical company used African Green Monkey kidneys to make hepatitis B vaccines; the kidney cells contained AIDS which remained present in the finished vaccine product in initial tests.

An interview with Dr. Maurice Hilleman (Merck pharmaceutical company vaccine division chief) by Dr Edward Shorter (medical historian) reveals this abominable truth and another equally disturbing admission that a cancer virus was loose in the 1950’s polio vaccines.

In Lies We Trust Part 14 of 16 by Dr. Leonard G. Horowitz

ES: Tell me how you found SV40 in the polio vaccine MH: I came to Merck and I was going to develop vaccines. We had wild viruses in those days, wild monkey kidney viruses and so forth. I finally after 6 months gave up, I said you can not develop vaccines with these dam monkeys, if I can’t do something about them I quit. So I went to see Bill Mann at Washington DC zoo and I told him, look I got a problem. These lousy monkeys are picking it up (viruses) while being stored at airports in transit. He said it is very simple, get your monkeys out of West Africa, get the African green, bring them into Madrid, unload them there, there are no other traffic through there for animals, fly them into Philadelphia and pick them up. So I brought African greens in. I didn’t know we were importing AIDS virus at the time.
ES: What Merck won’t do to develop a vaccine?

MH: This was the solution because those monkeys didn’t have the wild viruses.

ES: Why didn’t the greens have the wild viruses?

MH: Because they weren’t being infected in these group holding things with all the other 40 different viruses.

ES: But they had the ones they brought from the jungle though?

MH: Yeah they had those but there were relatively few. If you have a gang housing you are going to have an epidemic transmition of infection in a confined space. So anyway the greens came in and we were taking our seed stocks and now I’m discovering new viruses.

I got an invitation from the Sister Kenny Foundation (researched using live viruses), they asked me to come down and give a talk. I though what will I talk about? I know, I’ll talk about the detection of non detectable viruses. So now I got to have something you know that’s going to attract attention, so I thought gee, that dam SV40, I mean that dam vacuolating agent we have, I’m going to pick that particular one. That virus has got to be in the vaccines and it’s got to be in Sabin’s vaccine, so I quickly tested it and sure enough, it was in there.

ES: So you just took stocks of Sabin vaccine of the shelf here at Merck?

MH: No, it was made at Merck.

ES: You were making it for Sabin?

MH: Yeah, it was made before I came.

ES: But at this point Sabin is still doing these massive field trials?

MH: Yes, in Russia and so forth. So I got down and talked about the detection of non detectable viruses. I told Albert (Sabin), look Albert I’m going to talk about a virus that is in your vaccine. You’re going to get rid of it, don’t worry about it.

ES: What did he say?

MH: He said basically that this is just another obfuscation that is going to upset vaccines. I said you are right but we have a new era here of detection and the important thing is to get rid of these viruses.

ES: Why would he call it an obfuscation if it was a virus contaminating the vaccine?

MH: Well because there were 40 different viruses in these vaccines anyway that we were inactivating.

ES: But you weren’t inactivating his though?

MH: No, that’s correct. Yellow fever vaccine had leukemia virus in it; this is in the days of very crude science. So I talked to him about it (Sabin), he said why are you concerned about it? I said well I have a feeling in my bones that this virus is different. I don’t know why, I feel this virus may have some long term effects. He said what? I said cancer. I said Albert you are going to think I’m nuts but I just have that feeling.

In the mean time we had taken this virus and put it into hamsters. So we had this meeting and that was sought of the topic of the day, the jokes that were going around were that “We would win the Olympics because the Russians would all be loaded down with tumours”. This was where the vaccine was made and tested.

But anyway, we know it was in our seed stocks for vaccines. That virus, 1 in 10,000 particles is not inactivated by formaldehyde, it was good science at the time because that was what you did, and you didn’t worry about those wild viruses.

ES: So you discovered it (SV40 cancer virus) wasn’t being inactivated in the Salk (Jonas Salk polio vaccine)?

MH: Right, so then the next thing you know is 3 or 4 weeks after that, we found that there were tumours popping out of these hamsters.

Invention details a Monovalent Virus Harvest. Monovalent - one antigen only, for vaccinating against one specific pandemic only. Apart from the actual details of the invention, Baxter details general industry info of note in this patent, eg. –

[0029] e) treating said inactivated virus with a detergent, resulting in a preparation comprising antigens. Central to this procedure is that it is possible to reduce the number of steps performed on an active virus and thus the virus is inactivated after collection of the primary harvest prior to the detergent treatment and/or optional purification steps. [0041] in a further embodiment of the present invention, the cells use for cell culture and viral propagation may be primary cells or any cultured cell line. Examples of cells which may be used include mammalian (e.g., CHO, BHK, VERO, HELA, or perC6), avian and insect.

[0044] in embodiments of the invention, the virus is modified by detergent treatment to produce a modified whole virus or split virus vaccine. Suitable detergents include Tween 80 and Triton X100. [0056] in further embodiments a vaccine composition is provided which comprises one or more viral antigens. Such a composition can further comprise a pharmaceutical carrier and/or an adjuvant. A further aspect of the present invention is a pharmaceutical composition or preparation as vaccine comprising an antigen.
[0057] suitable adjuvants can be selected from mineral gels, aluminium hydroxide, lysolecithin, or oil emulsions.

[0062] three different influenza strains, two A-strains Hiroshima (HR, H3N2), a New Caledonia (NC, H1N1) and a B-strain, Malaysia (MA), were produced in Vero cell cultures.

[0079] Benzonase, a recombinant nuclease produced in E. coli, is added to the virus suspension at a final concentration of 3 U/ml to degrade cell derived DNA.

[0085] for virus splitting, Triton X100 is added to a final concentration of 0.5% (w/w) and incubated over night at room temperature.

[0089] formalin is added into the Ultra/Diaretentate to a final concentration of 0.025% for antigen stabilization. Formalin is a saturated acqueous solution of 36-37% formaldehyde gas.

[0104] for the New Caledonia strain at the end of purification, total Vero protein could be reduced from 8mg to 2mg from the Peak Pool to the Monovalent Bulk (MVB). Vero DNA content in the MVB was 0.27 µg. Total protein was reduced from 382mg to 162mg.

It is very interesting indeed what can be learned from reading pharmaceutical patents. Here is another made jointly by MedImmune Vaccines Inc. and the US Gov. NIH (National Institutes of Health). The patent is for Influenza Hemagglutinin and Neuraminidase Variants, filled Aug 2007.

Background info:

Hemagglutinin - rcsb.org

A spike-shaped protein that extends from the surface of the virus, the name to the ability of influenza to agglutinate red blood cells: the virus is covered with many hemagglutinin molecules, which together can glue many red blood cells together into a visible clump.

Neuraminidase - enzyme that removes sialic acid from mucoproteins and is found chiefly in microorganisms of the respiratory and intestinal tracts.

wikipedia

Human flu viruses have a neuraminidase enzyme, signified in the name "H#N#", where the H refers to an isoform of hemagglutinin and N refers to an isoform of neuraminidase.

Another pretext, the patent is concerned with producing peptides –
patentstorm.us

US Patent 5200320 - Method for identifying useful polypeptide vaccines In order to immunize an animal (including humans) against a particular infectious agent, it is necessary to activate T-cells specific for a protein (antigen) derived from the agent. It has previously been suggested that the final step in this activation of T helper cells is the creation of a trimolecular complex consisting of major histocompatibility complex (MHC) II molecules (Ia molecules), `processed` antigenic protein (both on antigen presenting cells -APC), and the T-cell receptor. As a necessary step in the formation of the foregoing complex, the processed antigen must bind to Ia molecules of the APC of the individual animal to be immunized. For a number of reasons, synthetic peptides derived from infectious agents may be useful as vaccines.

United States Patent Application Influenza Hemagglutinin and Neuraminidase Variants
Assignees: MedImmune Vaccines Inc., the Government of the United States of America National Institutes of Health

Filed: Aug 9, 2007

Abstract

Polypeptides, polynucleotides, methods, compositions and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. [0003] live attenuated virus vaccines have the advantage of being able to stimulate local mucosal immunity in the respiratory tract. Considerable work in the production of influenza viruses, and the fragments thereof, for production of vaccines has been done by the present inventors and co-workers.
[0004] because of the continual emergence (or re-emergence) of different influenza strains, new vaccines are continually desired. Such vaccines are created using antigenic moieties of the newly emergent virus strains, thus, polypeptides and polynucleotides of novel, newly emergent, or newly re-emergent virus strains (especially sequences of antigenic genes) are highly desirable.

[0005] the present invention provides new and/or newly isolated influenza hemagglutinin and neuraminidase variants that are capable of use in production of numerous types of vaccines.

[0009] Methods for stimulating the immune system of an individual to produce a protective immune response against influenza virus, through administering an immunologically effective amount of such recombinant influenza virus in a physiologically acceptable carrier are also part of the invention.

[0069] The term “host cell” means a cell that contains a heterologous nucleic acid, such as a vector, and supports the replication and/or expression of the nucleic acid. Host cells can be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, avian or mammalian cells, including human cells. Exemplary host cells can include, eg., Vero (African Green Monkey kidney) cells, BHK (baby hamster kidney) cells, primary chick kidney (PCK) cells, Madin-Darby Canine Kidney (MDCK) cells, Madin-Darby Bovine Kidney (MDBK) cells, 293 cells (eg., 293T cells), and COS cells (eg., COS1, COS7 cells), etc.

* 293T - Human Embryonic Kidney cells, also often referred to as HEK 293.
* COS cells - obtained by immortalizing (ability to proliferate indefinitely) a CV-1 cell line derived from African green monkey kidney cells with a version of the SV40 monkey virus genome.

[0076] various embodiments of the invention utilize A/Ann Arbor (AA)/6/60 influenza strain as a “backbone” upon which to add HA and/or NA genes to create desired reassortant viruses. [0078] Live attenuated influenza A virus vaccines against human influenza viruses were recently licensed in the US. Such vaccines are reassortant H1N1 and H3N2 viruses. Classical genetic reassortment and plasmid-based reverse genetics techniques have been applied to generate reassortant viruses that contain the Hemagglutinin and Neuraminidase genes from avian influenza A viruses. The generation and evaluation of these reassortant viruses as seed viruses for vaccines are important steps in pandemic preparedness.
[0080] The term “cold adapted” (ca) indicates that the virus exhibits growth at 25˚ C. within 100 fold of its growth at 33˚ C., while the term “attenuated” (att) indicates that the virus replicates in the upper airways of ferrets but is not detectable in their lung tissues.

[0088] A related aspect of the invention provides methods for stimulating the immune system of an individual to produce a protective immune response against influenza virus. In the methods, an immunologically effective amount of a recombinant influenza virus (eg., comprising an HA and/or NA molecule of the invention), an immunologically effective amount of a polypeptide of the invention, and/or an immunologically effective amount of a nucleic acid of the invention is administered to the individual in a physiologically acceptable carrier.

[0089] Generally, the influenza viruses of the invention are administered in a quantity sufficient to stimulate an immune response specific for one or more strains of influenza virus (i.e., against the HA and/or NA strains of the invention).

[0090] Typically, the attenuated recombinant influenza of this invention as used in a vaccine is sufficiently attenuated such that symptoms of infection, or at least symptoms of serious infection, will not occur in most individuals immunized (or otherwise infected) with the attenuated influenza virus. In some instances, the attenuated influenza virus can still be capable of producing symptoms of mild illness and/or dissemination to unvaccinated individuals.

[0093] Optionally, the formulation for prophylactic administration of the influenza viruses also contains one or more adjuvants for enhancing the immune response to the influenza antigens. Suitable adjuvants include: complete Freund’s adjuvant, aluminium hydroxide, oil or hydrocarbon emulsions, Bacille Calmette-Guérin (BCG) and Corynebacterium parvum.

[0125] The present invention also relates to host cells that are introduced (transduced, transformed or transfected) with vectors of the invention, and the production of polypeptides of the invention by recombinant techniques. Host cells are genetically engineered (i.e., transduced, transformed or transfected) with a vector, of this invention.

[0126] Most commonly, mammalian cells are used to culture the HA and NA molecules of the invention. Suitable host cells for the replication of influenza virus include, e.g., Vero cells, BHK cells, MDCK cells, 293 cells and COS cells. Commonly, co-cultures including two of the above cell lines, e.g., MDCK cells and either 293T or COS cells are employed at a ratio, e.g., of 1:1, to improve replication efficiency.

These two patents paint a horrific picture from the world of mad science vaccine production. The MedImmune/NIH patent is just mind boggling in the way it casually advocates for example that; suitable adjuvants include complete Freund’s adjuvant.

The classic oil-based adjuvant called Freund’s Complete Adjuvant can cause permanent organ damage and irreversible disease – specifically autoimmune diseases. When scientists want to induce autoimmune disease in a lab animal, they inject it with Freund’s Complete Adjuvant.

And the “suitable and/or exemplary host cells” for propagating the viruses that go into the vaccines, unbelievable! Chinese hamster, African Green Monkeys crossed with monkey virus genome, cancerous cells, human embryonic cells, dogs, and the icing on the cake, splicing dog and human embryonic cells together to “improve replication efficiency”.
The later patent is also most revealing in the disclosure that “In some instances, the attenuated influenza virus can still be capable of producing symptoms of mild illness and/or dissemination to unvaccinated individuals.”

Doctors have long known this to be true. Rima E. Laibow, MD writes in the publication “The Syringe of Death”

Vaccines have not eradicated diseases: vaccines spread diseases. Attenuated viruses (infective, weakened versions of the dangerous ones) are commonly used in vaccines. This practice derives from the dawn of vaccination: Edward Jenner’s pioneering use of cowpox pus inoculations to eliminate smallpox. It makes a wonderful story but, in fact, inoculation not only spread smallpox, it caused well-documented epidemics of syphilis and leprosy in inoculated people.
When a live virus is used in the vaccine, infective virus is shed for anywhere from 4 to 21 days (or more) and, during that time, inoculated persons can give the disease, or the side effects of the inoculation, to any vulnerable person they come into contact with.

Neither Jenner’s cowpox inoculation nor modern smallpox inoculation did anything to eliminate smallpox (quite the contrary). The fact is Dr. Charles Campbell discovered that smallpox is transmitted by the flying bedbug, Cimex lectularius, and that eliminating this parasitic insect from human habitation eliminates smallpox too. Personal hygiene and better housekeeping eliminated the deadly scourge. (Dr. Campbell also discovered that the disfiguring pocks of the disease could be prevented by a diet high in Vitamin C.)

When the World Health Organization (WHO) declared the planet “smallpox free” in 1980, they did so administratively, not medically: small pox incidence was reduced, but not gone, despite nearly universal vaccination. What to do? WHO solved the problem cleverly: they renamed the disease “cowpox” and “monkey pox”. Shazam: a smallpox free planet, quicker than you can say, “Junk Science!”

Despite the considerable hype, in fact, there is no unbiased evidence which connects disease prevention with inoculation.

The “Horrors of Vaccination Exposed and Illustrated” published in 1920 by Chas Higgins, Higgins writes of the 1918 Spanish H1N1 flu pandemic.

In a previous letter to the Secretary of War, dated October 14, 1918, I have pointed out the dangerous nature of vaccination, particularly during epidemics, and the hygienic importance of suspending all vaccination during our recent epidemic of influenza and pneumonia. I also then called attention to the probability that the repeated and multiple vaccinations of millions of men, in this country and Europe, with various septicemic infections for the last two years, may have had some relation to this epidemic, which seems to have been more severe among the vaccinated men in the military camps and hospitals than among the rest of the population.
From the rapidity, severity and mortality of this disease, it would seem not to be a true influenza as its worst cases are characterized by septic pneumonia, with abscesses in the lungs. This suspicion is strengthened by the fact that the chief germ found in the fatal cases is the “streptococcus,” which is found in the worst forms of blood poisoning or “septicemia.” The act of ordinary vaccination is in itself, an act of blood poisoning, pure and simple. It is also classed in medical and statistical works as a form of “septicemia” and one disease germ commonly found in vaccine virus is the streptococcus, which is the chief germ found in all bad pus infections and abscess formations.

Therefore, as the act of vaccination is simply the impregnation of the body and blood with a pus infection identical with “septicemia”, and this process has been repeated in tens of thousands of men closely massed in camps, should it be any wonder if an epidemic of some sort of “septicemia” should crop out at some time under such conditions?

Is it physically or medically possible to go on sowing and spreading some known and unknown septic diseases at wholesale, within human bodies, without reaping some big harvest of deadly septic diseases as a necessary consequence?